Healthtech & subsectors
Hampleton‘s Healthtech practice is headed by Jonathan Simnett and Dr. Jan Eiben. Our team’s relationships with investors, acquirers and entrepreneurs spans the globe from the Americas, through EMEA and into the Asia-Pacific region. It includes the most innovative vendors of relevant technologies such as AI, AR/VR, data analytics, computer vision, connected care, diagnostics, HRM, imaging systems, sensor technology, software, and much more.
The Hampleton team members have many years of experience advising companies in health services, medical technology, and pharmaceutical industries. With international experience in healthcare, life science, insurance and government, they have led transactions in archiving, electronic data interchange, governance, risk management, compliance, records and back office management systems.
We have worked for and closed transactions with companies such as Blue Shield, Certara, FBGS, Greenlight, Neoteryx and SAGlobal.
Hampleton recently guided the shareholders of Berlin-based BaseCase, creators of a data visualisation SaaS platform, in the sale of their company to the New Jersey-headquartered global leader in regulatory science, Certara, an EQT portfolio company. Bringing together a niche technology vendor and the right buyer with a full suite of synergistic products and services requires in-depth industry knowledge and experience. The BaseCase / Certara transaction highlights Hampleton’s understanding, creativity and capabilities in finding the best matches in healthtech, enterprise software and SaaS.
Featured transaction M&A
The sale of BaseCase to Certara
Hampleton Partners advised on the sale of Germany’s BaseCase data visualisation software as a service (SaaS) company to US-based Certara, the global leader in model-informed drug development and regulatory science. BaseCase‘s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians or healthcare providers.
By integrating content creation with sales enablement, it allows users to quickly create and personalize a visual value proposition around a drug or device’s ROI and business case.
Jonathan has been involved in the enterprise technology business for over three decades, managing and turning around existing business and helping management and their investors in fast-growth technology segments to grow, manage change, enter markets, transfer technologies, acquire, merge and sell. He’s worked with large and public infrastructure and system integration companies including: AT&T, Avaya, BroadSoft, BT, C&W, Cisco, HP, Global Switch, GMC, Huawei, Informix, Infosys, Intel, Myriad Group, Novell, IBM, IGT, Nortel, OpenReach, Pace, TCS, and Sybase.
Jan is based in Germany. His career over the last 15 years includes extensive experience in international M&A projects of various industries on the buy and sell sides. In addition, he also worked as a management consultant advising corporations, family businesses and start-ups in strategy and organizational development projects as well as succession management.
Jan holds a PhD and MSc in Business Administration and Economics from WHU - Otto Beisheim School of Management with exchange semesters in the USA and Canada. He is fluent in German (native), English and French.
Healthtech Report 1H2022
There is growing appetite to apply Artificial Intelligence (AI) and digital solutions to solve many of medicine's pressing problems. This was been exacerbated by the coronavirus pandemic in 2020.
Top Trends in Tech-Fundraising und -M&A - Wie ist der Bewertungshype zu verstehen?
Hampleton featured in Wall Street Journal, Forbes, Business Leader and more (2022)
Hampleton's reports have recently been featured in the Wall Street Journal and other media publications.